



PolTiss

TRANSFORMABLE POLYMER IMPLANT FOR

TISSUE REPAIR

We are on a mission to radically improve the safety and quality of life for patients and the comfort of surgeons






PROF. MIROSLAWA EL FRAY

Inventor, Professor at the West Pomeranian University of Technology, Szczecin, Poland

Expert in polymer and biomaterials engineering and science, author of >150 research papers, PI of over 15 research projects, holder of 12 patents

THE TECHNOLOGY



Material injected as a liquid



Transformation under UV light



Flexible & extremely adhesive patch in seconds

KEY ADVANTAGES



Raw materials based on natural and renewable resources



Slow degradation = no residual material in the body



Injectable liquids of tuneable viscosity



Especially suitable for laparoscopic and robotic surgeries (minimally invasive)



Fast procedure (transformation from liquid to solid in seconds)

STRONG

PhotoBioCure® TECHNOLOGY



Over 15 different formulas of materials with tuneable properties patented



New patents are being filed currently to explore new areas of application



Strong know-how and expertise in polymer chemistry and biomaterials



One formulation already tested for one medical application –
HERNIA REPAIR

IP PROTECTION

US/PL PATENTS GRANTED



ACKNOWLEDGED TECHNOLOGY






PRECLINICAL STUDIES OF ONE FORMULATION COMPLETED

- Confirmed biocompatibility (in compliance with the guidelines of ISO 10993)
- Confirmed functionality properties (defined as the lack of hernia recurrence)
- Slow biodegradation
- Lack of hemolytic, toxic, pyrogenic, genotoxic and allergic effects
- Mechanical properties matching well those of connective tissue of the human abdominal wall, thus providing sufficient mechanical strength
- Successful first implementations in patients.

The unmet need for innovation in current **HERNIA TREATMENT***

The use of a polypropylene (plastic) mesh net is the standard treatment in hernia repair surgery worldwide. But it comes with major potential challenges for patients and surgeons

	<p>Surgical complications</p> <ul style="list-style-type: none"> • Infection • Recurrence • Chronic pain • Seroma formation
	<p>Material harmful to environment & body</p> <ul style="list-style-type: none"> • Non-degradable material • Damaging to the environment • Will stay in your body
	<p>Time consuming procedure</p> <ul style="list-style-type: none"> • Mesh to be cut before application • Mesh to be sutured or tacked into place • Mesh in-optimal for minimally invasive procedures

The **MARKET** for hernia repairs

Tier 1 market, hernia mesh devices

€ 4,5 B (CAGR 3,1%)

TAM

Total Addressable

TAM: Hernia mesh devices market [global ARR]

€2,0 B

SAM

Serviceable addressable market

SAM: Inguinal and umbilical hernia mesh device market

€ 200 M

SOM

Serviceable obtainable market

SOM: 10% market share

* HERNIA MESH DEVICE MARKET - FORECAST (2022 - 2027)

€ 1,44 bn in the US, CAGR 3.2%

<https://www.marketdataforecast.com/market-reports/na-hernia-mesh-devices-market>

€ 1,11 bn in the EU, CAGR 2.8%

<https://www.marketdataforecast.com/market-reports/europe-hernia-mesh-devices-market>

*Hernia occurs when an internal part of the body pushes through a weakness in the muscle or surrounding tissue wall

**Sources: <https://www.gminsights.com/industry-analysis/hernia-repair-devices-market#:~:text=According%20to%20an%20article%20published,number%20of%20hernia%20repair%20procedures.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618132/>

*** Source: <https://link.springer.com/article/10.1007/s00268-018-4642-6>



OTHER MEDICAL APPLICATIONS

PHOTOBIOCURE® - MULTIPLE APPLICATIONS TO BE EXPLORED



Global Small bone and joint orthopedic devices market size and share analysis 2023-2028

€4,19 bn , CAGR 6,7%


<https://idataresearch.com/product/small-bone-and-joint-devices-market/>



Surgical Sealants and Adhesives market – forecast 2023- 2028

€5.19 bn, CAGR 9.6%

<https://www.marketdataforecast.com/market-reports/surgical-sealants-and-adhesives-market>



Aesthetic surgery



Cardiac surgery

OTHER MEDICAL APPLICATIONS


PHOTOBIOCURE® - MULTIPLE APPLICATIONS TO BE EXPLORED




Woundcare



Electrodes



Aesthetic surgery



Cardiac surgery



LEADERSHIP
PolTiss TEAM



PROF. MIROSLAWA EL FRAY

Board Member & founder

Inventor, Professor at the West Pomeranian University of Technology, Szczecin

Research cooperation with DePuy Johnson & Johnson, Uniqema/Croda, Honda, Europe, Philips.



TOMASZ LASECKI

Board Member COO & founder

Entrepreneur and consultant
Skilled in fundraising, business development

Investor in SDS Optic, PROSOMA. Partner in POMERANGELS VC
Former Managing Director in Amber Business Angels Network



GOKHAN DEMIRCI

CTO

Experienced Scientist with expertise in photocuring polymers

PhD at Maria-Curie Skłodowska University. Previous cooperation with Aston University (UK), Denmark Technical University (DK), Cyprus University of Technology (CY), Lodz Polytechnic (PL). 4 research projects.

ADVISORS

MEDICAL BOARD



Andrzej Ratajczak

M.D./PhD

Experienced Surgeon. Former President of Polish Hernia Society



Prof. Piotr Prowans

M.D.

Head of the Clinic of Plastic Surgery, Endocrinology and General Surgery, Pomeranian Medical University



Roman Kustos

Manager at Foundation of Cardiac Surgery Development – leading R&D centre for medical devices in Poland

PRODUCT/BUSINESS/REGULATORY



Joachim Kohn

Leader in the field of biomaterials science, Founder of New Jersey Centre for Biomaterials. His technologies were used in devices implanted to 350.000 patients in 46 countries



Karina Candrian

Partner in MEDICALBOARD 20 years' experience in the Healthcare industry (Synthes, Sunstar, Degradable Solutions).



Wojtek Faszczewski

Business angel Manager with experience in managing, sales and marketing of medical devices, working for a global medical device manufacturer



SOREN KELLER

Life science executive. Skilled in strategy, finance, business development, marketing & sales
Former CEO/COO/Board Member. Employed at Zealand Pharma, Bionor Pharma,


PolTiss

thomas@poltiss.com

